Growth Factor News and Research

RSS

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Research findings could lead to new targeted treatments for aggressive subtype of lymphoma

An international team of researchers, including Lukas Kenner from the Clinical Department of Pathology at MedUni Vienna, has discovered a specific combination of mutations and new gene fusions, which are heavily implicated in tumour growth in patients with a particularly aggressive subtype of lymphoma (ALCL).

11 May 2015

Researchers identify promising combination strategy for treating glioblastomas

Therapies that specifically target mutations in a person's cancer have been much-heralded in recent years, yet cancer cells often find a way around them. To address this, researchers at University of California, San Diego School of Medicine and Moores Cancer Center identified a promising combinatorial approach to treating glioblastomas, the most common form of primary brain cancer.

10 May 2015

Trained nurses administer AMD treatments as safely and effectively as doctors

Nurses trained to deliver eye injections for patients with the wet form of age-related macular degeneration (AMD) administered the treatments as safely and effectively as doctors, according to a new study. The research is being presented at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology this week in Denver, Colo.

6 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

No evidence for cancer risk with growth hormone therapy

There is no evidence that growth hormone (GH) therapy increases the likelihood of neoplasms in children with no additional risk factors, says the Pediatric Endocrine Society Drug and Therapeutics Committee.

1 May 2015

Study opens door for new therapeutic approaches to treating patients with melanoma

Weill Cornell Medical College researchers have shown for the first time that a gene previously implicated in blood vessel formation during embryonic development and tumor growth also induces immune suppression during tumor development.

30 Apr 2015

UI orthopedics researchers working on injectable, bioactive gel that can repair cartilage damage

Knee injuries are the bane of athletes everywhere, from professionals and college stars to weekend warriors. Current surgical options for repairing damaged cartilage caused by knee injuries are costly, can have complications, and often are not very effective in the long run. Even after surgery, cartilage degeneration can progress leading to painful arthritis.

29 Apr 2015

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

28 Apr 2015

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Herceptin has been touted as a wonder drug for women with HER2-positive breast cancer, an aggressive form of the disease that is fueled by excess production of the HER2 protein. However, not all of these patients respond to the drug, and many who do respond eventually acquire resistance.

28 Apr 2015

Study suggests that inhibiting FOXO1 protein could speed diabetic wound healing

A protein that normally fosters tissue repair instead acts to inhibit healing when sugar levels are high, according to a study in The Journal of Cell Biology. The role reversal helps explain why wounds heal slowly in people with diabetes.

28 Apr 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway.

25 Apr 2015

Scientists reveal how breast milk prevents necrotizing enterocolitis in premature babies

The immune-boosting properties of breast milk have long been known. Now a team of scientists led by Johns Hopkins pediatric surgeon-in-chief David Hackam, M.D., Ph.D., says experiments in mice reveal how breast milk works to ward off the development of necrotizing enterocolitis (NEC), a devastating intestinal disorder that affects 12 percent of premature babies and claims the lives of one in four of those who have it.

23 Apr 2015

New Tel Aviv University study may pave way for personalized bipolar disorder treatment

Rapidly swinging from extremes of joy and energy to sadness, fatigue, and confusion, bipolar disorder (BD) patients feel desperate and largely alone in the world. And according to the National Institutes of Health, between 25-50 percent of the roughly 3% of Americans living with BD attempt suicide at least once.

23 Apr 2015

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Vasoproliferative ocular diseases are responsible for sight loss in millions of people in the industrialised countries. Many patients do not currently respond to the treatment offered, which targets a specific factor, VEGF. A team of Inserm researchers at the Vision Institute (Inserm/CNRS/Pierre and Marie Curie University), in association with a team from the Yale Cardiovascular Research Center, have demonstrated in an animal model that blocking another protein, Slit2, prevents the pathological blood vessel development that causes these diseases.

22 Apr 2015

Growth Factor News and Research

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Research findings could lead to new targeted treatments for aggressive subtype of lymphoma

Researchers identify promising combination strategy for treating glioblastomas

Trained nurses administer AMD treatments as safely and effectively as doctors

Researchers identify multiple types of resistance to new targeted lung cancer drug

No evidence for cancer risk with growth hormone therapy

Study opens door for new therapeutic approaches to treating patients with melanoma

UI orthopedics researchers working on injectable, bioactive gel that can repair cartilage damage

First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Study suggests that inhibiting FOXO1 protein could speed diabetic wound healing

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Study identifies BLU-554 as potential treatment option for HCC patients

Scientists reveal how breast milk prevents necrotizing enterocolitis in premature babies

New Tel Aviv University study may pave way for personalized bipolar disorder treatment

Blocking Slit2 protein prevents blood vessel development that causes vasoproliferative ocular diseases

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

Insulin signaling pathway has significant influence on the growth of glioblastomas

Study: 1 in 4 patients with advanced lung cancer does not receive EGFR test results before treatment

Scientists identify way to potentially predict progression in patients with early form of breast cancer

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News